Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07698366
Recruiting Not applicable

Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial

NCT07698366 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Not applicable
Started
2026-09-20
Last updated
2026-09-28

Condition(s) studied

Breast NeoplasmsEarly Detection of Cancer

Investigational drug(s) / intervention(s)

Standardized Breast Ultrasound Screening

Standardized Breast Ultrasound Screening: One standardized breast ultrasound examination performed and interpreted by a qualified physician, with further clinical evaluation of abnormal findings as appropriate.

Study summary

This multicenter, cluster randomized trial will evaluate whether community-based breast ultrasound screening improves the early detection of breast cancer in women aged 65 to 80 years, compared with routine health management. Approximately 80,000 women in Jiangsu Province, China, will be enrolled and followed for breast cancer outcomes.

Eligibility

Sex
FEMALE
Min age
65 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female participants aged 65-80 years. * Local residents living in participating communities for ≥6 months. * Signed informed consent and willingness to participate. Exclusion Criteria: * History of breast cancer or previous breast cancer treatment. * Breast cancer screening within the past 2 years. * Severe comorbid conditions that may affect study participation or follow-up. * Acute breast disease or conditions requiring immediate treatment. * Unable to cooperate with screening procedures due to physical or cognitive limitations.

Primary outcome measure(s)

  • Absolute difference in early-stage breast cancer diagnosis rate — 24 months after enrollment
    The between-group absolute difference in the proportion of pathologically confirmed breast cancer cases diagnosed at stage I or II.

Trial sites (2)

FacilityCityRegionStatus
Kunshan First People's Hospital Kunshan Jiangsu Recruiting
The Fourth Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu Not Yet Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

Effect of Digital Therapeutics for Cardiac Rehabilitation in Patients With Acute Myocardial Infarction Starting soon
Gestational Lifestyle & Outcomes Wellness Recruiting
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial Recruiting
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma Recruiting
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes Recruiting

Other trials for the same condition

Robotic-Assisted vs. Endoscopic-Assisted Sentinel Lymph Node Biopsy in Breast Cancer Active, not recruiting
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen Recruiting
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients Recruiting
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer Recruiting
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07698366 on ClinicalTrials.gov ↗ ← All trials in China